8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 9, 2013, Pages 3495-3500

  Jiao, Bo ^a   Ren, Zhi Hong ^a,b   Liu, Ping ^a   Chen, Li Juan ^a,c   Shi, Jing Yi ^a   Dong, Ying ^a   Ablain, Julien ^d   Shi, Lin ^a   Gao, Li ^a   Hu, Jun Pei ^b   Ren, Rui Bao ^a   De Thé, Hugues ^a,d   Chen, Zhu ^a   Chen, Sai Juan ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Leukemogenesis; NcoR1; PKA pathway; PML RAR ; SMRT

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; RETINOIC ACID; SERINE; THYROID HORMONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA ZINC FINGER GENE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RETINOIC ACID RECEPTOR ALPHA GENE; SURVIVAL RATE; TRANSACTIVATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, INBRED C57BL; NUCLEAR RECEPTOR CO-REPRESSOR 2; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PHOSPHOSERINE; PROTEOLYSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; THIONUCLEOTIDES; TRANSLOCATION, GENETIC; TRETINOIN;

EID: 84874456701     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1222863110     Document Type: Article

References (33)

1. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD (2001) Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 20(49): 7186-7203.
2. Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111(5): 2505-2515.
3. Licht JD, et al. (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85(4): 1083-1094.
4. Jansen JH, et al. (1999) Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 94(1): 39-45.
5. Petti MC, et al. (2002) Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 100(3): 1065-1067.
6. Chen L-J, et al. (2005) [hCG-PLZF-RARalpha/hCG-RARalpha-PLZF transgenic mice developing into leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13(6): 924-931.
7. Zhao Q, et al. (2004) Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia 18(2): 285-292.
8. Zhu Q, et al. (2002) Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99(3): 1014-1022.
9. Guillemin MC, et al. (2002) In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 196(10): 1373-1380.
10. Cheng GX, et al. (1999) Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci USA 96(11): 6318-6323.
11. He LZ, et al. (2000) Two critical hits for promyelocytic leukemia. Mol Cell 6(5): 1131-1141.
12. Ruthardt M, et al. (1997) Opposite effects of the acute promyelocytic leukemia PMLretinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol 17(8): 4859-4869.
13. Delghandi MP, Johannessen M, Moens U (2005) The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell Signal 17(11): 1343-1351.
14. Gaillard E, et al. (2006) Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7. Proc Natl Acad Sci USA 103(25): 9548-9553.
15. Nasr R, et al. (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14(12): 1333-1342.
16. Rice KL, et al. (2009) Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood 114(27): 5499-5511.
17. Spinello I, et al. (2009) PLZF-mediated control on c-kit expression in CD34(+) cells and early erythropoiesis. Oncogene 28(23): 2276-2288.
18. Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA (2010) Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 116(1): 81-84.
19. Wojiski S, et al. (2009) PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 23(8): 1462-1471.
20. Guibal FC, et al. (2009) Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 114(27): 5415-5425.
21. Grignani F, et al. (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391(6669): 815-818.
22. Guidez F, et al. (1998) Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91(8): 2634-2642.
23. Mengeling BJ, Phan TQ, Goodson ML, Privalsky ML (2011) Aberrant corepressor interactions implicated in PML-RAR(alpha) and PLZF-RAR(alpha) leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants. J Biol Chem 286(6): 4236-4247.
24. Insinga A, et al. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11(1): 71-76.
25. Lamb D, Steinberg RA (2002) Anti-proliferative effects of 8-chloro-cAMP and other cAMP analogs are unrelated to their effects on protein kinase A regulatory subunit expression. J Cell Physiol 192(2): 216-224.
26. Altucci L, et al. (2005) Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res 65(19): 8754-8765.
27. Nasr R, de Thé H (2010) Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int J Hematol 91(5): 742-747.
28. Ablain J, de The H (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117(22): 5795-5802.
29. Chen S-J, et al. (2011) From an old remedy to a magic bullet: Molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117(24): 6425-6437.
30. Testa U, et al. (1994) PML/RAR alpha+ U937 mutant and NB4 cell lines: Retinoic acid restores themonocytic differentiation response to vitamin D3. Cancer Res 54(16): 4508-4515.
31. Grignani F, et al. (1993) The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74(3): 423-431.
32. Westervelt P, et al. (2002) Adaptive immunity cooperates with liposomal all-transretinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc Natl Acad Sci USA 99(14): 9468-9473.
33. Tsimberidou A-M, et al. (2006) Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: An update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma 47(6): 1062-1068.